(176aw) Rifampicin-Cyclodextrin Inclusion Complexes Formulated for Pulmonary Drug Delivery | AIChE

(176aw) Rifampicin-Cyclodextrin Inclusion Complexes Formulated for Pulmonary Drug Delivery

Authors 

Freeman, M. - Presenter, University of Rhode Island
Barneman, S., University of Rhode Island
Meenach, S., University of Rhode Island
Shen, J., University of Rhode Island

Rifampicin (RIF) is an antibiotic commonly used in the treatment of tuberculosis, a bacterium that infects one fourth of the world’s population. RIF is integral in the effective treatment of tuberculosis, however, current treatment regimens require frequent and prolonged dosing, leading to decreased patient compliance and, thus, potentially drug resistant tuberculosis. This project aims to provide an alternative to oral RIF drug delivery by means of an inhalable spray-dried powder formulation. Directing RIF delivery to the lungs can minimizes systemic side effects and increase drug concentration at the site of infection. This particular formulation involves the complexation of RIF with two types of modified cyclodextrins (CD) in order to improve RIF and control the release of RIF upon delivery of the powder formulation to the lungs Furthermore, a RIF-CD formulation may improve lung delivery by allowing for higher drug concentrations at the site of infection. RIF-CD complexes were studied to determine their physicochemical characteristics, ability to enhance RIF solubility, and pulmonary deposition characteristics. In particular, RIF-CD inclusion complexes were formed by a RIF-solvent solution with a CD-water solution. This mixture was then spray dried to form the final dry powder RIF-CD complexes. These formulations were then analyzed via phase solubility, scanning electron microscopy (size and morphology), x-ray diffraction and differential scanning calorimetry (crystallinity and phase transitions), Karl Fischer titration (water content), dissolution (RIF release), and Next Generation Impactor (aerosol dispersion). Overall, these formulations have the potential to improve the solubility and control the release of RIF while being effectively deposited in the pulmonary tract.